Group 1 - Rani Therapeutics has entered into a securities purchase agreement for the sale of 4,354,000 shares of Class A common stock at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999 per share [1][2] - The offering is expected to close on or about July 16, 2025, with gross proceeds estimated at approximately $3.0 million before deducting fees and expenses [2] - The securities are being offered under a "shelf" registration statement declared effective by the SEC on August 10, 2022, and a final prospectus supplement will be filed with the SEC [3] Group 2 - Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and drugs, including the RaniPill® capsule [4] - The RaniPill® capsule is designed to replace subcutaneous injections or intravenous infusions with oral dosing, and the company has conducted several studies to evaluate its safety and bioavailability [4]